HC Wainwright Predicts TG Therapeutics Q1 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for TG Therapeutics in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst E. White forecasts that the biopharmaceutical company will post earnings of $0.28 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q2 2025 earnings at $0.32 EPS, Q3 2025 earnings at $0.37 EPS and Q4 2025 earnings at $0.42 EPS.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

A number of other brokerages have also recently issued reports on TGTX. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Stock Performance

TGTX opened at $35.11 on Thursday. The business’s 50-day simple moving average is $30.86 and its 200 day simple moving average is $28.33. TG Therapeutics has a 52-week low of $12.93 and a 52-week high of $36.94. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market capitalization of $5.47 billion, a PE ratio of -351.06 and a beta of 2.30.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On TG Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in TG Therapeutics by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company’s stock valued at $469,454,000 after purchasing an additional 209,190 shares during the period. State Street Corp lifted its holdings in shares of TG Therapeutics by 35.8% during the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after buying an additional 2,398,015 shares in the last quarter. Soleus Capital Management L.P. boosted its position in shares of TG Therapeutics by 5.8% in the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock valued at $80,705,000 after acquiring an additional 146,702 shares during the period. Clearbridge Investments LLC acquired a new position in shares of TG Therapeutics in the fourth quarter valued at about $55,237,000. Finally, Northern Trust Corp increased its position in TG Therapeutics by 8.6% during the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock worth $46,141,000 after acquiring an additional 120,785 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.